incretin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
=== Loeys–Dietz syndrome === TGF-β signaling is also disturbed in Loeys–Dietz syndrome which can be caused by mutations in TGF-β proteins, TGF-β receptor proteins, or TGF-β signaling second messengers like SMAD3.
By the early modern period, Neo-Latin had become the lingua franca of science, medicine, legal discourse, theology, and education in Europe. Over time, the use of Latin continued where international communication with specialist audiences was paramount. Later, where some of the discourse moved to French, English or German, translations into Latin would allow texts to cross language boundaries, while authors in countries with much smaller language populations or less known languages would tend to continue to compose in Latin. Latin's dominance over medicine began to change in the late seventeenth century, as philosophers and others began to write in their native language first, afterwards translating into Latin for international audiences. In the early part of the 1700s, Latin was still making a significant contribution to academic publishing, but was no longer dominant. Examples of modern medical dictionaries include Mosby's Dictionary of Medicine, Nursing & Health Professions, Stedman's, Taber's, and Dorland's.
=== Among male homosexuals === A study undertaken at Utrecht University found that the majority of gay men in the study regarded a large penis as ideal, and having one was linked to self-esteem. One study analysing the self-reported Kinsey data set found that the average penis of a homosexual man was larger than the average penis of their heterosexual counterparts (6.32 inches [16.05 cm] in length amongst gay men versus 5.99 in [15.21 cm] in heterosexuals, and 4.95 inches [12.57 cm] circumference amongst gay men versus 4.80 in [12.19 cm] in heterosexual men).
Sources: en.wikipedia.org
In response, AbbVie announced that it would cease enforcing its patents on the drug entirely. In May 2021, Allergan Aesthetics announced the acquisition of Soliton. In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118. In October, the company acquired DJS Antibodies for $225 million, giving it access to an experimental drug for an aggressive lung disease as well as technology to develop certain antibody medicines. In January 2023, Humira began facing competition from biosimilars. In February 2024, AbbVie acquired ImmunoGen for $10.1 billion, aiming to expedite its entry into the ovarian cancer treatment market with ImmunoGen's drug Elahere. In the same month, AbbVie and Tentarix Biotherapeutics announced the beginning of a long-term collaboration in the discovery and development of opportunistic, multi-specific biological candidates in oncology and immunology. AbbVie provides expertise in these areas, and will also provide Tentarix with option advances worth $64 million for two programs, and Tentarix will provide its patented Tentarix Tentacles™platform. AbbVie also received an option to purchase the software in full. In March 2024, the company announced it would acquire Landos Biopharma for over $200 million. In June 2024, Robert Michael replaced Richard Gonzalez as CEO of AbbVie.
Most nitrogenases contain an iron–molybdenum cofactor FeMoco, which is believed to contain either Mo(III) or Mo(IV). By contrast Mo(VI) and Mo(IV) are complexed with molybdopterin in all other molybdenum-bearing enzymes. Molybdenum is an essential element for all higher eukaryote organisms, including humans. A species of sponge, Theonella conica, is known for hyperaccumulation of molybdenum.
Another turning point in this timeframe for Dick is the alleged burglary of his home and theft of his papers. After delivering "The Android and the Human", Dick became a participant in X-Kalay (a Canadian Synanon-type recovery program), effortlessly convincing program caseworkers that he was nursing a heroin addiction to do so. Dick's recovery program participation was portrayed in the posthumously released book The Dark Haired Girl (a collection of letters and journals from this period, most of a romantic nature). It was at X-Kalay, while doing publicity for the facility, that he devised the notion of rehab centers being used to secretly harvest drugs (thus inspiring the book's New-Path clinics). In the afterword, Dick dedicates the book to those of his friends—he includes himself—who had experienced debilitation or death as a result of their drug use. Mirroring the epilogue are the involuntary goodbyes that occur throughout the story—the constant turnover and burn-out of young people that lived with Dick during those years. In the afterword, he states that the novel is about "some people who were punished entirely too much for what they did", and that "drug misuse is not a disease, it is a decision, like the decision to move out in front of a moving car".
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。